RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oncology Pharma Stock

Oncology Pharma Net Income 2024

Oncology Pharma Net Income

-186,040 USD

Ticker

ONPH

ISIN

US68235J2015

WKN

A2QEWD

In 2024, Oncology Pharma's profit amounted to -186,040 USD, a -365.09% increase from the 70,180 USD profit recorded in the previous year.

The Oncology Pharma Net Income history

YEARNET INCOME (undefined USD)
2013-186.04
201170.18
201058.73
2004-1,565
2003-1,520
2002-1,951
2001-1,590
2000-4,520
1999-1,490
1998-2,770
1997-3,020

Oncology Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Oncology Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Oncology Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Oncology Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Oncology Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Oncology Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Oncology Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Oncology Pharma’s growth potential.

Oncology Pharma Revenue, EBIT and net profit per share

DateOncology Pharma RevenueOncology Pharma EBITOncology Pharma Net Income
201310,210 undefined-14,480 undefined-186,040 undefined
2011156,000 undefined70,980 undefined70,180 undefined
2010134,700 undefined59,520 undefined58,730 undefined
20041.18 M undefined-1.7 M undefined-1.57 M undefined
20033.28 M undefined-1.63 M undefined-1.52 M undefined
20023.67 M undefined-2.02 M undefined-1.95 M undefined
20014.01 M undefined-1.82 M undefined-1.59 M undefined
2000990,000 undefined-4.75 M undefined-4.52 M undefined
1999740,000 undefined-1.57 M undefined-1.49 M undefined
1998890,000 undefined-2.48 M undefined-2.77 M undefined
19971.28 M undefined-2.84 M undefined-3.02 M undefined

Oncology Pharma stock margins

The Oncology Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oncology Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oncology Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Oncology Pharma's sales revenue. A higher gross margin percentage indicates that the Oncology Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Oncology Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Oncology Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Oncology Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Oncology Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Oncology Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Oncology Pharma Margin History

Oncology Pharma Gross marginOncology Pharma Profit marginOncology Pharma EBIT marginOncology Pharma Profit margin
201344.62 %-141.82 %-1,822.14 %
201144.62 %45.5 %44.99 %
201044.62 %44.19 %43.6 %
200444.62 %-144.03 %-132.51 %
200363.05 %-49.54 %-46.34 %
200263.02 %-54.9 %-53.13 %
200160.35 %-45.39 %-39.65 %
200027.27 %-479.8 %-456.57 %
199937.84 %-212.16 %-201.35 %
199830.34 %-278.65 %-311.24 %
199734.38 %-221.88 %-235.94 %

Oncology Pharma Aktienanalyse

What does Oncology Pharma do?

Oncology Pharma Inc is a global biotechnology company working on the development of therapies and medications against various types of cancer. The company was founded in the USA in 2011 and is headquartered in Boston, Massachusetts. Its business model is based on developing and marketing medications focused on fighting cancer. The company specializes in targeted therapies, immunotherapies, and combination therapies. Oncology Pharma's products have the potential to revolutionize cancer treatment and improve the lives of millions of people worldwide. Oncology Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Oncology Pharma's Profit Margins

The profit margins of Oncology Pharma represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Oncology Pharma's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Oncology Pharma's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Oncology Pharma's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Oncology Pharma’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Oncology Pharma stock

How much profit has Oncology Pharma made this year?

Oncology Pharma has made -186,040 USD this year.

How has the profit developed compared to last year?

The profit has increased by -365.09% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Oncology Pharma publish its earnings?

Oncology Pharma publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Oncology Pharma?

The profits of Oncology Pharma are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Oncology Pharma?

You can learn more about the earnings of Oncology Pharma by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Oncology Pharma pay?

Over the past 12 months, Oncology Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncology Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Oncology Pharma?

The current dividend yield of Oncology Pharma is .

When does Oncology Pharma pay dividends?

Oncology Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oncology Pharma?

Oncology Pharma paid dividends every year for the past 0 years.

What is the dividend of Oncology Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oncology Pharma located?

Oncology Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oncology Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oncology Pharma from 9/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Oncology Pharma pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of Oncology Pharma in the year 2023?

In the year 2023, Oncology Pharma distributed 0 USD as dividends.

In which currency does Oncology Pharma pay out the dividend?

The dividends of Oncology Pharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oncology Pharma

Our stock analysis for Oncology Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncology Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.